Ganciclovir hydrate

Synonyms: 更昔洛韦水合物; BW-759 hydrate; 2'-Nor-2'-deoxyguanosine hydrate
Ganciclovir (BW 759) hydrate 是一种核苷类似物和口服抗病毒活性分子,对 CMV 具有抗病毒活性,并在体外对疱疹病毒 (herpes group) 和其他一些 DNA 病毒也具有抗病毒活性,可抑制人类疱疹病毒 (HSV 1 型和 2 型,CMV) 和腺病毒血清型 1、2、4、6、8、10、19、22 和 28 的体外复制,对猫 1 型疱疹病毒 (FHV-1) 的 IC50 为 5.2 μM,且可透过大脑屏障。
产品编号: MS-R66189 CAS No.: 1359968-33-4 分子式: C9H15N5O5 分子量: 273.25
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Ganciclovir (BW 759) hydrate 是一种核苷类似物和口服抗病毒活性分子,对 CMV 具有抗病毒活性,并在体外对疱疹病毒 (herpes group) 和其他一些 DNA 病毒也具有抗病毒活性,可抑制人类疱疹病毒 (HSV 1 型和 2 型,CMV) 和腺病毒血清型 1、2、4、6、8、10、19、22 和 28 的体外复制,对猫 1 型疱疹病毒 (FHV-1) 的 IC50 为 5.2 μM,且可透过大脑屏障。

生物实验数据

生物活性 Ganciclovir (BW 759) hydrate is a nucleoside analog and orally active antiviral molecule with antiviral activity against CMV, and it also exhibits antiviral activity in vitro against herpes group viruses and some other DNA viruses, inhibiting the in vitro replication of human herpesviruses (HSV types 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22, and 28, with an IC50 of 5.2 μM against feline herpesvirus type 1 (FHV-1) and the ability to cross the blood-brain barrier.
IC50 & Target FHV-1:5.2 μM
体外研究
(In Vitro)

Ganciclovir (BW 759) is an acyclic deoxyguanosine analog structurally similar to acyclovir but with superior activity against CMV. The median Ganciclovir concentration required to inhibit viral replication by 50 percent is 2.15 μM versus 72 μM for acyclovir.
The primary mechanism of Ganciclovir action against CMV is inhibition of the replication of viral DNA by ganciclovir-5'-triphosphate (ganciclovir-TP). This inhibition includes a selective and potent inhibition of the viral DNA polymerase. Ganciclovir is metabolized to the triphosphate form by primarily three cellular enzymes: a deoxyguanosine kinase induced by CMV-infected cells; guanylate kinase; and phosphoglycerate kinase.

体内研究
(In Vivo)

Ganciclovir (BW 759) (50 mg/kg; i.p.; twice a day for five injections) significantly decreases white blood cells, red blood cells and platelets in newborn mice, and can diffuse into the brain and the perilymphatic space of the inner ear.
Ganciclovir (1-80 mg/kg; i.h.; daily for 5 days) delays murine cytomegalovirus (MCMV)-induced wasting syndrome and mortality.

Animal Model: Non-inbred Oncins France 1 (OF1) mice and albino rats non-immunized for MCMV
Dosage: 50 mg/kg
Administration: Intraperitoneal injection, twice a day for five injections (mice) or 3 days (adult rats) (Pharmacokinetic Study)
Result: In adult rats, the intracochlear diffusion of Ganciclovir was shown to achieve the same concentration as in blood. In gestating mice, transplacental diffusion was observed, with a fetal-to-maternal blood ratio of 0.5. In newborn mice, the plasma concentration profile of Ganciclovir showed a peak at 2 h followed by a gradual decrease. In adult mice, the concentration peaked at 1 h, but became undetectable by 2 h after injection.
Significantly decreased white blood cells, red blood cells and platelets in newborn mice.
Animal Model: Female SCID mice inoculated with MCMV
Dosage: 0, 1, 10, 80 and 160 mg/kg
Administration: Subcutaneous injection, once daily for 5 days
Result: Dose dependently delayed the wasting syndrome and mortality in a dose range up to 80 mg/kg per day, whereas a dose of 160 mg/kg per day induced reversible side-effects.

化学信息

分子量 273.25
分子式 C9H15N5O5
CAS No. 1359968-33-4
别名 更昔洛韦水合物; BW-759 hydrate; 2'-Nor-2'-deoxyguanosine hydrate

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础